Disease Areas |
NEUROLOGY |
RARE DISEASE |
ONCOLOGY |
CARDIOVASCULAR |
||||||
Modalities |
||||||||||
GENE THERAPY |
RNA |
SMALL MOLECULES |
BIOLOGICS |
Modalities |
Sohang Chatterjee
Co-Founder, CEO and Director
Praesidia Biotherapeutics, Inc. (Private)
“As we look at the last six months of working with Allele in completing our Series A financing, we are delighted we decided to work with them… an extension of management team… fair and forthcoming with partnership terms…. helped prepare and refine our corporate deck, rehearse interactions with investors, and fine tune our corporate strategy and timelines."
MoreHoward Berman, PhD
Co-Founder and CEO
Coya Therapeutics, Inc. (NASDAQ: COYA)
“Coya is funded today because of the expertise and professionalism of the Allele Capital Team… superior knowledge of science and capital markets… understood our value proposition and asked the right questions… cost to access capital is much lower than traditional VCs, and much faster"
MoreEric I. Richman,
CEO & Director
Gain Therapeutics, Inc. (NASDAQ: GANX)
“Working with Allele dramatically reduced our execution risk… Extensive knowledge in life sciences and capital markets contacts… Entire team contributed… Proprietary investment, institutional and accredited investors, partnership approach."
MoreDavid Moss,
Co-Founder & CFO
INmune Bio, Inc. (NASDAQ: INMB)
“A first-class organization… Knowledge of how to navigate banking and institutional universe is second to none… Advice was instrumental … They have helped build and finance private and public biotech for many years”
MoreDietrich Stephan, PhD
Founder, Chairman and CEO
NeuBase Therapeutics, Inc. (NASDAQ: NBSE)
"World-class professionals … extension of our team, plan and execute capital markets strategy… Deep understanding of the segment, excellent network (investors, board talent, bankers, analysts).… highest integrity - cannot recommend them highly enough.“
MoreRobert Finizio,
Co-Founder & CEO
TherapeuticsMD, Inc. (NASDAQ: TXMD)
"…Advised us on various aspects of our corporate planning and to assist us in raising capital… support us in our company’s growth initiatives through investment, advice and capital markets support… Allele is a value-added advisor and investor"
MoreShai Novik,
Former CEO
Prolor Biotech, Inc. - Acquired by OPKO Health, Inc. (NASDAQ: OPK) in 2013
“… Shared our vision and believed in our team pre Proof of Concept… Identified risk mitigated scientific strategy of proprietary versions of approved proteins… Invested their own capital and used their network to become a champion of our company“
More